Samsara Vision, Inc. (SMSA)
Samsara Vision will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$5.00 - $7.00
Shares Offered
2,500,000
Deal Size
$15.00M

Company Description

Samsara Vision is a specialty medical device company dedicated to bringing vision and freedom back to patients suffering from late-stage conditions of the retina.

We are engaged in the research, development, manufacturing, and marketing of proprietary ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders, particularly Age-Related Macular Degeneration (“AMD”).

Our current product line consists of: our first-generation implantable miniature telescope ("IMT"), which we refer to as WA IMT; our Smaller-Incision, New Generation (SING) IMT; and our Tsert delivery system.

Our WA IMT, approved by the FDA in July 2010 and received a Conformité Européenne Mark (“CE Mark”) in August 2005, works similarly to the telephoto lens of a camera, which enables improvement in vision and quality of life for individuals with the most advanced form of AMD.

We received a CE Mark by mdc medical device certification GmbH, an EEA Notified Body for our SING IMT and Tsert delivery system in April 2020 and began commercializing our SING IMT in Europe in 2021.

In addition, we are in the process of establishing the regulatory pathway into the United States.

Samsara Vision, Inc.
Country United States
Founded 1997
Industry Health Care Equipment & Supplies
Sector Healthcare
Employees 20
CEO Thomas Ruggia

Contact Details

Address:
27 US HWY 202 (Ste 8/9)
Far Hills, NJ 07931
United States
Phone (877) 997-4448
Website samsaravision.com

Stock Details

Ticker Symbol SMSA
Exchange NASDAQ
Reporting Currency USD
CIK Code 0001824988
Employer ID 47-5178400
SIC Code 3841